JP2017529851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529851A5 JP2017529851A5 JP2017516350A JP2017516350A JP2017529851A5 JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5 JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- car
- cell
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055979P | 2014-09-26 | 2014-09-26 | |
| US62/055,979 | 2014-09-26 | ||
| PCT/US2015/052227 WO2016049459A1 (en) | 2014-09-26 | 2015-09-25 | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529851A JP2017529851A (ja) | 2017-10-12 |
| JP2017529851A5 true JP2017529851A5 (enExample) | 2018-11-08 |
Family
ID=55582053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516350A Pending JP2017529851A (ja) | 2014-09-26 | 2015-09-25 | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170281683A1 (enExample) |
| EP (2) | EP3858991A1 (enExample) |
| JP (1) | JP2017529851A (enExample) |
| DE (1) | DE20196219T1 (enExample) |
| ES (2) | ES2844700T3 (enExample) |
| WO (1) | WO2016049459A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| CN121102467A (zh) | 2016-04-22 | 2025-12-12 | 克莱格医学有限公司 | 用于细胞免疫疗法的组合物和方法 |
| JP2019530431A (ja) | 2016-07-26 | 2019-10-24 | テッサ・セラピューティクス・プライベート・リミテッド | キメラ抗原受容体 |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| JP2018093823A (ja) * | 2016-12-15 | 2018-06-21 | Ｈｅａｒｔｓｅｅｄ株式会社 | 未分化幹細胞除去剤及び未分化幹細胞除去方法 |
| MX2019008221A (es) * | 2017-01-10 | 2019-12-09 | Univ Yamaguchi | Anticuerpo anti-gpc3. |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| EP3441461A1 (en) * | 2017-08-11 | 2019-02-13 | Baylor College of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CA3102641A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| US20210261646A1 (en) * | 2018-07-03 | 2021-08-26 | Sotio, LLC | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020017479A1 (ja) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| JP7456638B2 (ja) | 2018-08-14 | 2024-03-27 | ソティオ，リミティド ライアビリティ カンパニー | クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用 |
| SG11202103234RA (en) | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| AU2019374828A1 (en) * | 2018-11-07 | 2021-05-27 | Sotio, LLC | Anti-GPC3 chimeric antigen receptors (CARs) in combination with trans co-stimulatory molecules and therapeutic uses thereof |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| EP4219688B1 (en) * | 2018-12-19 | 2026-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| MX2021010840A (es) | 2019-03-08 | 2022-01-19 | Obsidian Therapeutics Inc | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. |
| KR20210150446A (ko) * | 2019-04-04 | 2021-12-10 | 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 | 종양 항원 인식 수용체를 함유하는 면역 세포 및 이의 적용 |
| JP2022537670A (ja) | 2019-06-12 | 2022-08-29 | オブシディアン セラピューティクス， インコーポレイテッド | Ｃａ２の組成物および調整可能な制御方法 |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN114391021B (zh) | 2019-06-21 | 2026-01-16 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CA3170023A1 (en) * | 2020-02-27 | 2021-09-02 | Nanjing Legend Biotech Co., Ltd. | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
| WO2021186395A1 (en) * | 2020-03-18 | 2021-09-23 | Eutilex Co., Ltd. | Gpc3 car- t cells secreting il-18 and methods of making and using the same |
| CN115667500B (zh) * | 2020-03-18 | 2026-02-06 | 优特力克斯有限公司 | Gpc3 car-t细胞组合物及其制备和使用方法 |
| JP2023535371A (ja) | 2020-07-17 | 2023-08-17 | シミュレックス インコーポレイテッド | 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法 |
| CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| US20240181055A1 (en) | 2021-04-08 | 2024-06-06 | Crage Medical Co., Limited | Cellular immunotherapy use |
| GB202105686D0 (en) * | 2021-04-21 | 2021-06-02 | Imperial College Innovations Ltd | Chimeric antigen receptor (CAR)-T cells |
| GB202105684D0 (en) * | 2021-04-21 | 2021-06-02 | Imperial College Innovations Ltd | Chimeric antigen receptor (CAR)-T cells |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| AU2022388928A1 (en) * | 2021-11-16 | 2024-05-16 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| CN117230174A (zh) * | 2023-04-03 | 2023-12-15 | 上海交通大学医学院附属瑞金医院 | Gpc3在诊断特发性肺纤维化中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ES2373055T3 (es) * | 2005-08-09 | 2012-01-31 | Oncotherapy Science, Inc. | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. |
| EP2699603B1 (en) * | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| EP3326467B1 (en) * | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| WO2014138314A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| ES2883240T3 (es) * | 2015-08-03 | 2021-12-07 | Cafa Therapeutics Ltd | Anticuerpo contra glipicano-3 y aplicación del mismo |
-
2015
- 2015-09-25 JP JP2017516350A patent/JP2017529851A/ja active Pending
- 2015-09-25 WO PCT/US2015/052227 patent/WO2016049459A1/en not_active Ceased
- 2015-09-25 DE DE20196219.8T patent/DE20196219T1/de active Pending
- 2015-09-25 EP EP20196219.8A patent/EP3858991A1/en active Pending
- 2015-09-25 ES ES15845117T patent/ES2844700T3/es active Active
- 2015-09-25 ES ES20196219T patent/ES2851123T1/es active Pending
- 2015-09-25 US US15/513,900 patent/US20170281683A1/en not_active Abandoned
- 2015-09-25 EP EP15845117.9A patent/EP3198010B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529851A5 (enExample) | ||
| Mizukoshi et al. | Immune cell therapy for hepatocellular carcinoma | |
| JP2021506243A5 (enExample) | ||
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2019527557A5 (enExample) | ||
| JP2016534717A5 (enExample) | ||
| JP2019528769A5 (enExample) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2017513478A5 (enExample) | ||
| JP2016502512A5 (enExample) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2019532668A5 (enExample) | ||
| JP2017522862A5 (enExample) | ||
| JP2018506981A5 (enExample) | ||
| MY186846A (en) | Method and compositions for cellular immunotherapy | |
| JP2017518037A5 (enExample) | ||
| JP2016508728A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
| JP2017538401A5 (enExample) | ||
| EP4537839A3 (en) | Method and compositions for cellular immunotherapy | |
| JP2015509717A5 (enExample) |